Motley FoolWhere does Macquarie think CSL shares will go from here?
What impact will this week's bad news have longer term? The post Where does Macquarie think CSL shares will go from here? appeared first on The Motley Fool Australia.
CSL LIMITED ORDINARY (CSL) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineCSL (ASX:CSL) Shares Back in Focus as Healthcare Giant Rebuilds
Highlights CSL (ASX:CSL) is attracting fresh attention as investors reassess the healthcare giant following a prolonged share price decline. A resilient plasma business and continued underlying earnings growth are helping reinforce confidence in the company's long-term fundamentals. Delays to the Seqirus separation and ongoing restructuring remain key themes shaping market sentiment. Australian equities continue to navigate a changin...
Why Are CSL (ASX:CSL) Shares Rallying as Healthcare Roars Back?
Highlights CSL (ASX:CSL) led a strong rebound across Australia's healthcare sector as market sentiment shifted. Capital rotated away from resource companies into defensive healthcare names, lifting sector leaders. Recent restructuring efforts have placed CSL back in focus as confidence gradually improves. Australia's share market staged a welcome recovery as money flowed back into healthcare, with biotechnology giant CSL (ASX:CSL) em...
Why Is CSL (ASX:CSL) Central to Healthcare Rebound?
Highlights ASX healthcare stocks are being tested on earnings confidence, not just valuation relief. Large medical names remain in focus as the market looks for cleaner operating proof. Clinical credibility, market breadth and cost control are shaping the next sector screen. ASX healthcare stocks are being tested through quality rebound, with earnings confidence, clinical credibility and margin ...
CSL (ASX:CSL): Why Could Healthcare Repair Lift Bluechips?
Highlights ASX bluechip stocks are being tested on earnings confidence and operational delivery. Healthcare repair is becoming important after recent sector turbulence. BHP, CSL, Telstra and Wesfarmers show different large-cap resilience signals. ASX bluechip stocks are being tested on healthcare confidence, operational delivery and valuation discipline as readers look for stronger evidence of l...
Why Is CSL (ASX:CSL) Framing Blue-Chip Resilience?
Highlights ASX bluechip stocks are being assessed through defensive cashflow and resilience. CSL, Telstra and Wesfarmers help frame different large-cap defensive signals. Market attention is shifting toward repeatable earnings, balance-sheet strength and crowded positioning. ASX bluechip stocks are being tested through defensive cashflow, margin discipline and resilience as readers compare healt...
Why Is CSL (ASX:CSL) Back in the ASX 200 Value Spotlight?
Highlights Market tone reflects uneven sector behaviour across the ASX Quality names revisit valuation focus amid earnings resilience signals Asset strength and cash flow remain central to investor attention ASX value stocks are under review as de-rated quality themes return, with earnings resilience, asset backing, and sector rotation shaping sentiment across the Australian market landscape. The discussion around ASX value stocks is shifting as d...
CSL (ASX:CSL): Are AI Imaging Deals Changing Healthcare Valuations?
Highlights AI imaging partnerships are becoming a stronger signal across healthcare names. CSL, Telix Pharmaceuticals, DMedical and Echo IQ show different sides of the healthcare technology screen. Market focus is shifting from headline momentum to commercial channels, clinical progress and defensive earnings. AI imaging partnerships are becoming a sharper valuation signal across Australian healthcare, as the market looks for companies that can combine medical...
Why Is CSL (ASX:CSL) Facing Its Toughest Healthcare Test in Years?
Highlights CSL has slipped to its lowest level in a decade as selling pressure weighs heavily on Australia's healthcare sector. Capital has increasingly rotated towards resource and energy companies while major healthcare names have fallen out of favour. Broader weakness has also affected Cochlear and ResMed, highlighting changing market leadership across Australian equities. CSL has returned to...
Another CSL blow: Why this beaten-up ASX giant is sliding again
This ASX blue chip is still trying to rebuild trust. The post Another CSL blow: Why this beaten-up ASX giant is sliding again appeared first on The Motley Fool Australia.
Why Is CSL (ASX:CSL) Back on the Radar for Blue-Chip Investors?
Highlights CSL continues strengthening its core healthcare operations despite a challenging period for its share performance. Demand for plasma therapies and specialty medicines remains supported by long-term healthcare trends. The company's diversified global business continues to underpin its position among Australia's leading healthcare names. CSL remains one of Australia's leading biotechnol...
ASX
Why Is CSL (ASX:CSL) Back on Healthcare Watchlists After Its Slide?
Highlights CSL (ASX:CSL) is regaining attention following a challenging period for Australia's healthcare sector. A strategic business review has reset expectations around its plasma and vaccines operations. Healthcare companies are once again drawing interest as market sentiment begins to stabilise. CSL continues strengthening its healthcare business through a strategic reset, operational f...
Why this fundie is overweight CSL and underweight CBA shares
Blackwattle Large Cap Quality Fund managers Joe Koh and Elan Miller explain their strategy. The post Why this fundie is overweight CSL and underweight CBA shares appeared first on The Motley Fool Australia.
Why is CSL (ASX:CSL) reshaping its bluechip story now?
Highlights CSL is advancing a broad restructuring aimed at improving long-term operational focus. The planned Seqirus separation is central to the company’s strategic reset. Market sentiment is reassessing CSL’s position within Australia’s leading bluechip cohort. CSL is undergoing restructuring and preparing a Seqirus demerger, reshaping its bluechip identity as investors reassess its str...
Once untouchable, now unloved: What's up with CSL shares?
CSL's stunning fall has investors questioning its comeback prospects. The post Once untouchable, now unloved: What's up with CSL shares? appeared first on The Motley Fool Australia.
Why Is ASX 200 CSL (ASX:CSL) Under Pressure as the Healthcare Giant Battles a Tough Reset?
Highlights CSL (ASX:CSL) remains under pressure after a downgraded outlook and a major impairment linked to its Vifor business. A broad transformation program aims to improve efficiency through substantial long-term cost reductions. The healthcare sector is watching whether CSL can restore earnings momentum and rebuild market confidence. CSL is navigating one of its most challenging periods as w...
$10,000 invested in CSL shares 12 months ago is now worth…
What happened to a CSL investment in the last year? The post $10,000 invested in CSL shares 12 months ago is now worth… appeared first on The Motley Fool Australia.
Healthcare Stocks: Why (ASX:CSL) Is at the Centre of the Valuation Reset
Highlights Healthcare stocks are being reassessed through a healthcare valuation reset as market participants place greater emphasis on earnings quality and execution. CSL (ASX:CSL), Pro Medicus (ASX:PME), Cochlear (ASX:COH) and ResMed (ASX:RMD) highlight how different healthcare business models are attracting different levels of attention. The key theme is that healthcare quality is being tested rather than automatically rewarded, making company-specific performan...
CSL Share Price ASX: Is the Biotech Giant Finally Finding a Floor?
Highlights CSL Limited has returned to focus after a deep reset from former blue-chip highs. Recent pressure has been linked to guidance concerns, impairments and uncertainty across key divisions. The latest rebound has raised fresh questions about whether confidence is stabilising. CSL share price ASX searches are rising as the healthcare giant rebounds from heavy pressure, with market focus on earnings clarity, divisional performance and confidence repair. The csl share price asx trend is g...
Why Are CSL (ASX:CSL) Shares Rebounding After Heavy Selloff?
Highlights CSL (ASX:CSL) shares rebound as investors return to heavily sold healthcare names. The stock had previously fallen to levels not seen in roughly a decade. A softer revenue outlook and strategic review continue to shape sentiment. CSL (ASX:CSL) has rebounded after a steep healthcare selloff, with investors reassessing valuation resets, revised guidance and long-term structural strengths. Australian healthcare stocks have returned to the spotlight, with CSL (ASX:CSL), one of th...
CSL (ASX:CSL) Shares Under Pressure: What Is Driving the Weakness?
Highlights CSL remains under intense market scrutiny following a prolonged share price decline and softer sentiment. Attention continues to focus on the performance of the Vifor business and broader earnings recovery efforts. The healthcare leader remains one of Australia's most influential companies despite recent operational challenges. CSL continues attracting attention as market participants evaluate healthcare demand, earnings recovery efforts, operational execution and the performance o...
Down 54%: What should I do with my CSL shares now?
Is sentiment changing course again? The post Down 54%: What should I do with my CSL shares now? appeared first on The Motley Fool Australia.
Is this broker right about CSL shares?
Investors no longer treat CSL like a flawless compounder, and that shift may be where the opportunity begins. The post Is this broker right about CSL shares? appeared first on The Motley Fool Australia.
Why Is CSL (ASX:CSL) Under Pressure as Its Biggest Reset Takes Shape?
Highlights CSL (ASX:CSL) is undergoing a significant strategic overhaul following weaker operating performance and revised expectations. Leadership transition, restructuring initiatives and operational efficiency have become key focus areas for the healthcare giant. Market attention is centred on whether the company's transformation efforts can restore momentum across its core businesses. CSL remains one of Australia's most closely watched healthcare companies as restructuring, leadersh...
What Could Put CSL (ASX:CSL) Back in the Healthcare Spotlight?
Highlights ASX healthcare shares have faced heavy pressure as market attention shifted toward cyclical sectors. CSL, Cochlear and ResMed remain central names in the healthcare sector debate. Lower sector valuations have renewed focus on quality healthcare franchises and recovery signals. ASX healthcare shares remain under pressure as CSL, Cochlear and ResMed face valuation resets, earnings scrutiny and shifting market sentiment after a difficult sector rotation. ASX healthcare shares ha...
CSL (ASX:CSL) and ASX Healthcare Stocks: Is the Defensive Premium Returning?
Highlights Healthcare shares are back under the spotlight as markets reassess the value of defensive earnings amid a volatile trading environment. CSL, ResMed and Sonic Healthcare remain key names shaping sentiment across the healthcare sector. The next phase for healthcare stocks may depend on cash flow quality, margin recovery and execution rather than market narratives alone. The Australian share market is navigating a period of heightened uncertainty, with commodity swings, shifting rate ...
CSL (ASX:CSL): ASX 200 Push Faces a Volume Test
Highlights The ASX 200 is being watched near a key resistance zone as traders look for volume confirmation. CSL (ASX:CSL), BHP Group (ASX:BHP) and Macquarie Group (ASX:MQG) sit near the centre of the current technical watchlist. Breadth, sector rotation and moving averages may decide whether the latest move shows real conviction or fades quickly. The ASX 200 faces a technical test near resistance, with volume confirmation, breadth and sector leadership likely to decide whether the move carrie...
Why A2 Milk, Calix, CSL, and Ioneer shares are charging higher today
These shares are having a strong session on Tuesday. What's going on? The post Why A2 Milk, Calix, CSL, and Ioneer shares are charging higher today appeared first on The Motley Fool Australia.
Down 53%, is it time to throw in the towel on CSL shares?
A leading analyst delivers his verdict on CSL’s plunging share price. The post Down 53%, is it time to throw in the towel on CSL shares? appeared first on The Motley Fool Australia.
CSL (ASX:CSL) or ResMed (ASX:RMD): Which Healthcare Giant Is Back in the Spotlight?
Highlights CSL and ResMed continue attracting attention after extended periods of share price weakness. Both companies operate in global healthcare markets supported by long-term structural demand trends. Healthcare remains one of the most closely watched sectors as markets focus on innovation, ageing populations and medical technology adoption. CSL and ResMed remain closely watched healthcare leaders as long-term demand trends, innovation and global healthcare needs continue shaping the sect...
Should I buy CSL and ResMed shares right now?
These healthcare giants have fallen heavily. Is now a good time to buy? The post Should I buy CSL and ResMed shares right now? appeared first on The Motley Fool Australia.
3 reasons why experts think CSL shares are a sell
Earnings pressure and downgrades weigh heavily on the biotech stock. The post 3 reasons why experts think CSL shares are a sell appeared first on The Motley Fool Australia.
CSL, ResMed and Cochlear: Is Healthcare’s Comeback Just Beginning?
Highlights Healthcare stocks are regaining attention as defensive growth themes re-emerge amid a cautious Australian market backdrop. CSL (ASX:CSL), ResMed (ASX:RMD) and Cochlear (ASX:COH) are highlighting different paths to earnings resilience and valuation recovery. EOFY positioning, geopolitical tensions and company-specific catalysts are making stock selection more important than broad sector momentum. The Australian share market is entering a more selective phase, with traders balancing ...
Is CSL (ASX:CSL) Becoming a Value Play After Its Sharp 2026 Drop?
Highlights CSL faces renewed attention as its steep 2026 decline attracts bargain-focused buyers. Plasma business and earnings reset shape shifting sentiment across healthcare stocks. Market reassessment builds across the ASX 200 healthcare segment. CSL faces renewed valuation debate after a sharp 2026 decline, with investors reassessing its plasma business, earnings outlook, and long-term role in Australia’s healthcare sector. Australian equities have entered a phase where long-s...
Google NewsCSL (ASX:CSL) Shares in Focus as Defensive Healthcare Rotation Puts Biotech Giant Back in Focus - Kalkine
CSL (ASX:CSL) Shares in Focus as Defensive Healthcare Rotation Puts Biotech Giant Back in Focus Kalkine
Why Is Blue-Chip CSL (ASX:CSL) Rebounding in the ASX 200?
Highlights CSL Limited regains strong investor attention after a sharp rebound in recent trading sessions. Blue-chip biotech sentiment improves as buyers return to high-quality healthcare names. Market focus shifts back to CSL’s core plasma and global biotechnology leadership. CSL Limited has regained investor attention following a notable rebound, with renewed focus on its global plasma leadership, biotechnology strength, and long-term role within the Australian healthcare sector...
Buy, hold, sell: Life360, Woodside, CSL shares
The market is lower today as two experts explain their ratings on these three ASX 200 shares. The post Buy, hold, sell: Life360, Woodside, CSL shares appeared first on The Motley Fool Australia.
What’s Driving CSL (ASX:CSL) ASX 20 After Its Latest Strategic Reset?
Highlights CSL continues to draw attention as investors assess its restructuring-led transformation journey. The company’s global plasma and biotechnology footprint remains central to its long-term direction. Market sentiment is increasingly focused on operational efficiency and portfolio alignment. CSL remains a leading biotechnology company with global operations. Market attention is centred on restructuring efforts, operational efficiency and its long-term role in advanced heal...
CSL (ASX:CSL) ASX 200 and ASX Healthcare Momentum: Key Scans Driving Attention?
Highlights Healthcare, gaming, property and tech stocks are showing mixed technical signals across ASX scans. Market momentum is shifting as investors reassess growth versus defensive positioning. Several large-cap and mid-cap names are appearing in technical breakout discussions. ASX market scans reveal mixed momentum across healthcare, gaming, property and technology sectors, with companies like CSL, REA Group and Aristocrat Leisure drawing attention. Australia’s share market co...
Is CSL’s (ASX:CSL) Trading Surge and Restructuring Reviving Confidence in Its Core Business Model? - simplywall.st
Is CSL’s (ASX:CSL) Trading Surge and Restructuring Reviving Confidence in Its Core Business Model? simplywall.st
Why CSL, Westpac, and this big-name ASX 200 share could be sells - The Motley Fool Australia
Why CSL, Westpac, and this big-name ASX 200 share could be sells The Motley Fool Australia
CSL (ASX:CSL): Why Are These Market Giants Facing Fresh Questions?
Highlights CSL, Steadfast Group and Wesfarmers remain closely watched due to evolving business developments and sector-specific challenges. Market attention is focused on earnings visibility, acquisition activity and operational execution across the three companies. Each business continues to hold a significant position within its respective sector despite changing market conditions. CSL, Steadfast and Wesfarmers continue attracting attention through healthcare innovation, insurance distribut...
CSL (ASX:CSL) and ASX 200 Healthcare Shift: What’s Fueling Fresh Market Attention?
Highlights Healthcare emerged as one of the strongest-performing sectors on the Australian share market recently. Leading healthcare companies helped drive renewed momentum after a prolonged period of weakness. Market attention is returning to the sector as sentiment shows signs of improvement. Healthcare stocks have returned to the spotlight on the Australian market, with leading companies helping improve sector sentiment and reigniting discussion around the industry’s broader re...
Buy, hold, sell: CSL, Steadfast, and Wesfarmers shares
Ord Minnett has given its verdict on these shares. The post Buy, hold, sell: CSL, Steadfast, and Wesfarmers shares appeared first on The Motley Fool Australia.
If I invest $8,000 in CSL shares, how much passive income will I receive in 2027?
This business could deliver healthy payouts in the next few years… The post If I invest $8,000 in CSL shares, how much passive income will I receive in 2027? appeared first on The Motley Fool Australia.
The bull and bear case for CSL shares
What are the realistic prospects for this once powerful healthcare company? The post The bull and bear case for CSL shares appeared first on The Motley Fool Australia.
CSL (ASX:CSL) Leads Healthcare Comeback, But Is the Rally Real?
Highlights Healthcare stocks staged a strong rebound as capital rotated away from resource-focused sectors. CSL, Cochlear, ResMed, Pro Medicus and Telix led a broad-based recovery across the healthcare space. Markets are now watching whether the move signals a lasting turnaround or a short-lived sentiment shift. The Australian share market has spent much of the year rewarding resource companies while many healthcare names struggled under pressure from softer earnings expectations and rising o...
CSL (ASX:CSL): Biotech Blue Chip Divides Investors as Share-Price Weakness Sparks Debate - Kalkine
CSL (ASX:CSL): Biotech Blue Chip Divides Investors as Share-Price Weakness Sparks Debate Kalkine
Why CSL (ASX:CSL) Is Sharing the Spotlight With EVN and CBA for Income Seekers
Highlights CSL, Evolution Mining and Commonwealth Bank continue attracting attention from income-focused market participants. The three companies offer exposure to healthcare, mining and banking, creating sector diversification opportunities. Strong market positions and established operations remain key themes supporting interest in these businesses. CSL, Evolution Mining and Commonwealth Bank continue attracting attention through their established positions in healthcare, mining and banking ...
After a Brutal Slide, Could CSL Be Preparing a Comeback?
Highlights CSL has remained under pressure over the past year, drawing significant attention across the Australian healthcare sector. Market expectations remain mixed, with analysts divided between a cautious and constructive outlook. The biotechnology giant continues focusing on long-term growth across plasma therapies, vaccines, and specialty medicines. CSL remains a major focus within Australia's healthcare sector as analysts evaluate valuation, innovation capabilities, and the company's p...
How much could the CSL share price rise in the next year?
Can this business deliver very healthy gains from here? The post How much could the CSL share price rise in the next year? appeared first on The Motley Fool Australia.
Investors are buying CSL shares again. Should you?
Some experts believe that 2026 could mark the low point for the biotech company. The post Investors are buying CSL shares again. Should you? appeared first on The Motley Fool Australia.
Healthcare Stocks Catch Breath as CSL Sparks Rebound
Highlights CSL (ASX:CSL) drives a sharp rebound in ASX healthcare after extended weakness. Sector rotation away from resources lifts defensive healthcare names across the market. Investors question whether improving sentiment signals a lasting shift or short-term bounce. ASX healthcare stocks have rebounded sharply, led by CSL, as sector rotation and valuation resets bring defensive names back into focus within the ASX 200 environment. ASX healthcare shares have re-emerged in focus afte...
3 reasons I'd buy CSL shares in FY27
It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering. The post 3 reasons I'd buy CSL shares in FY27 appeared first on The Motley Fool Australia.
ASX 200 Healthcare Watch: CSL (ASX:CSL) Valuation Debate Deepens
Highlights CSL Limited draws attention as market expectations shift ahead of its upcoming earnings update. The biotechnology leader continues to anchor Australia’s global healthcare presence across plasma and specialty therapies. Valuation discussions intensify as investors reassess long-term growth versus current market pricing. CSL is under renewed focus ahead of earnings as valuation discussions intensify. The biotechnology leader continues to anchor Australia’s healthcar...
CSL (ASX:CSL) Shares Could Be 31.5% Undervalued Before Full Year Results - simplywall.st
CSL (ASX:CSL) Shares Could Be 31.5% Undervalued Before Full Year Results simplywall.st
Is Healthcare Turning? CSL Leads ASX Sector Bounce
Highlights CSL (ASX:CSL) leads a broad lift across Australian healthcare equities after an extended period of pressure. Cochlear (ASX:COH) and ResMed (ASX:RMD) remain central to the sector’s re-rating discussion following earlier declines. Sector rotation dynamics across the ASX 200 are bringing renewed attention to defensive healthcare names. ASX healthcare equities see renewed attention as CSL leads sentiment shift, while Cochlear, ResMed and Sigma Healthcare reflect a more segm...
CSL shares jump 15%: Is it time to start buying the beaten-down biotech stock?
CSL shares have climbed 7% higher over the past week alone. The post CSL shares jump 15%: Is it time to start buying the beaten-down biotech stock? appeared first on The Motley Fool Australia.
CSL shares trade at just 12 times forecast earnings. Here's why they could be the buy of the decade
The ASX 200 healthcare giant is down more than 60% since August 2025. The post CSL shares trade at just 12 times forecast earnings. Here's why they could be the buy of the decade appeared first on The Motley Fool Australia.